Obtaining oxygen without the need to breathe might soon be possible thanks to a groundbreaking medical advancement addressing critical hypoxemia. Researchers at Boston Children’s Hospital have developed pH-sensitive microbubbles that inject oxygen directly into the bloodstream—offering a promising and effective alternative during respiratory arrest. This innovation could redefine emergency medicine.

15 Years Designing Injectable Oxygen

For over a decade, Dr. John Kheir and Dr. Yifeng Peng worked on a disruptive solution for emergencies where conventional oxygenation fails. Their idea: polymer-encapsulated, pH-sensitive microbubbles capable of releasing oxygen directly into the blood. In initial trials, lipid bubbles showed promise but would collapse and risk embolism if administered too quickly.

Their second design used hollow polymer microparticles—but these proved inefficient at oxygen delivery. It was only on the third attempt that they created a polymer-coated microbubble that dissolves rapidly in contact with blood pH, releasing between 350 and 500 mL of oxygen per liter of microbubbles. These stable storage bubbles became key to moving forward toward clinical solutions.

In animal models (pigs) experiencing severe hypoxemia due to airway obstruction, intravenous injection of these microbubbles quickly restored oxygen levels, reduced cardiac arrests, and significantly improved neurological and kidney function. The polymer shells dissolved without causing toxicity or embolism.

This finding represents the first demonstration of safety and effectiveness in delivering significant amounts of oxygen via injected gas in large animals. This intravenous therapy could become a vital tool during cardiac arrest or hypoxemic shock, serving as a bridge until ventilators or ECMO can be deployed.

Challenges, Regulation, and Future Applications

With strong animal data, the researchers have already secured funding from Harvard to move toward clinical-scale production and FDA approval. The next steps include establishing manufacturing protocols that meet regulatory standards and ensuring industrial reproducibility.

This microbubble system also offers a platform for delivering other medical gases, paving the way for applications from neonatal emergencies to radiotherapy support and cardiovascular procedures.

Challenges include ensuring rapid dissolution to avoid vascular blockage and calibrating safe dosage. Additionally, the fluid volume associated with microbubble administration in humans must be carefully adjusted to prevent circulatory overload. Still, the success in pigs provides a solid foundation: fast oxygenation, organ protection, and no toxicity.

The next phase will involve conducting human clinical trials to validate safety, tolerability, and efficacy. If successful, this could become an unprecedented medical tool to save lives when every second without oxygen counts.

After 15 years of refinement and successful animal testing, injectable oxygen via polymer-sensitive microbubbles is poised for human trials and may revolutionize emergency medicine when both time and oxygen are scarce.

Reference:

• Nature Biomedical Engineering/Systemically injected oxygen within rapidly dissolving microbubbles improves the outcomes of severe hypoxaemia in swine. Link

Esta entrada también está disponible en: Español